Experience with hormonal therapy in advanced epithelial ovarian cancer

Nine van der Vange, Stefano Greggi, Curt W. Burger, Peter Kenemans, Jan B. Vermorken

Research output: Contribution to journalArticlepeer-review


The experience from using different hormonal trials in 33 ovarian cancer patients, who were beyond the stage of standard therapies and experimental cytotoxic therapies in a single institution, are reported. Agents used were progestins, an antiestrogen (tamoxifen), an antiandrogen (flutamide) and a GnRH-agonist (decapeptyl). Twenty-one patients completed at least 8 weeks of treatment. Two patients obtained an objective response (10%: one partial response on tamoxifen for 6 months and one complete response on decapeptyl for 38 + months. Two further patients achieved disease stabilizations on tamoxifen and flutamide for 6 and 8 months respectively. Although the objective response rate with hormonal therapies is limited in these circumstances the absence of important toxicities favor their use. It is suggested to further study this in patients who do not reach a complete response after standard induction chemotherapy, particularly in those with well-differentiated tumors.

Original languageEnglish
Pages (from-to)813-820
Number of pages8
JournalActa Oncologica
Issue number6
Publication statusPublished - 1995

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Hematology


Dive into the research topics of 'Experience with hormonal therapy in advanced epithelial ovarian cancer'. Together they form a unique fingerprint.

Cite this